[8-K] Kindly MD, Inc. Reports Material Event
KindlyMD (NASDAQ:NAKA) filed an 8-K announcing the appointment of Andrew Creighton as Chief Commercial Officer of Nakamoto Holdings. The filing indicates this is a Regulation FD disclosure, with the information being furnished rather than filed under Section 18 of the Securities Exchange Act. The company, which is classified as an emerging growth company, made this announcement via press release on June 25, 2025.
KindlyMD (NASDAQ:NAKA) ha presentato un modulo 8-K annunciando la nomina di Andrew Creighton come Chief Commercial Officer di Nakamoto Holdings. Il documento specifica che si tratta di una comunicazione ai sensi del Regulation FD, con le informazioni fornite e non depositate ai sensi della Sezione 18 del Securities Exchange Act. La societ脿, classificata come azienda in crescita emergente, ha reso noto l'annuncio tramite un comunicato stampa il 25 giugno 2025.
KindlyMD (NASDAQ:NAKA) present贸 un formulario 8-K anunciando el nombramiento de Andrew Creighton como Director Comercial de Nakamoto Holdings. El documento indica que se trata de una divulgaci贸n conforme al Regulation FD, con la informaci贸n proporcionada y no archivada bajo la Secci贸n 18 del Securities Exchange Act. La empresa, clasificada como compa帽铆a de crecimiento emergente, hizo este anuncio mediante un comunicado de prensa el 25 de junio de 2025.
KindlyMD (NASDAQ:NAKA)電� Nakamoto Holdings鞚� 斓滉碃 靸侅梾 毂呾瀯鞛愲 Andrew Creighton鞚� 鞛勲獏頄堧嫟瓿� 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 氤搓碃靹滊姅 Regulation FD 瓿店皽 靷暛鞛勳潉 氇呾嫓頃橂┌, 歃濌秾瓯半灅氩� 鞝�18臁办棎 霐半澕 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 鞝曤炒鞛勳潉 雮橅儉雰呺媹雼�. 鞁犿潵 靹膘灔 旮办梾鞙茧 攵勲霅橂姅 鞚� 須岇偓電� 2025雲� 6鞗� 25鞚� 氤措弰鞛愲毳� 韱淀暣 鞚� 靻岇嫕鞚� 氚滍憸頄堨姷雼堧嫟.
KindlyMD (NASDAQ:NAKA) a d茅pos茅 un formulaire 8-K annon莽ant la nomination d鈥橝ndrew Creighton en tant que Chief Commercial Officer de Nakamoto Holdings. Le d茅p么t indique qu鈥檌l s鈥檃git d鈥檜ne divulgation conforme au Regulation FD, les informations 茅tant fournies plut么t que d茅pos茅es en vertu de la Section 18 du Securities Exchange Act. La soci茅t茅, class茅e comme une entreprise en croissance 茅mergente, a fait cette annonce via un communiqu茅 de presse le 25 juin 2025.
KindlyMD (NASDAQ:NAKA) hat ein 8-K-Formular eingereicht, in dem die Ernennung von Andrew Creighton zum Chief Commercial Officer von Nakamoto Holdings bekannt gegeben wird. Die Einreichung weist darauf hin, dass es sich um eine Offenlegung gem盲脽 Regulation FD handelt, wobei die Informationen bereitgestellt und nicht gem盲脽 Abschnitt 18 des Securities Exchange Act eingereicht wurden. Das Unternehmen, das als wachstumsstarkes Unternehmen eingestuft ist, gab diese Mitteilung am 25. Juni 2025 per Pressemitteilung bekannt.
- None.
- None.
Insights
Executive appointment signals potential commercial expansion but relationship between entities requires clarity.
The appointment of Andrew Creighton as Chief Commercial Officer of Nakamoto Holdings, while disclosed by KindlyMD, raises interesting governance considerations. The filing's structure suggests an important relationship between KindlyMD and Nakamoto Holdings that isn't fully explained in this disclosure. The choice to file this under Regulation FD indicates the information is deemed material enough for broad public dissemination, though technically not filed under Section 18 of the Exchange Act.
KindlyMD (NASDAQ:NAKA) ha presentato un modulo 8-K annunciando la nomina di Andrew Creighton come Chief Commercial Officer di Nakamoto Holdings. Il documento specifica che si tratta di una comunicazione ai sensi del Regulation FD, con le informazioni fornite e non depositate ai sensi della Sezione 18 del Securities Exchange Act. La societ脿, classificata come azienda in crescita emergente, ha reso noto l'annuncio tramite un comunicato stampa il 25 giugno 2025.
KindlyMD (NASDAQ:NAKA) present贸 un formulario 8-K anunciando el nombramiento de Andrew Creighton como Director Comercial de Nakamoto Holdings. El documento indica que se trata de una divulgaci贸n conforme al Regulation FD, con la informaci贸n proporcionada y no archivada bajo la Secci贸n 18 del Securities Exchange Act. La empresa, clasificada como compa帽铆a de crecimiento emergente, hizo este anuncio mediante un comunicado de prensa el 25 de junio de 2025.
KindlyMD (NASDAQ:NAKA)電� Nakamoto Holdings鞚� 斓滉碃 靸侅梾 毂呾瀯鞛愲 Andrew Creighton鞚� 鞛勲獏頄堧嫟瓿� 8-K 氤搓碃靹滊ゼ 鞝滌稖頄堨姷雼堧嫟. 鞚� 氤搓碃靹滊姅 Regulation FD 瓿店皽 靷暛鞛勳潉 氇呾嫓頃橂┌, 歃濌秾瓯半灅氩� 鞝�18臁办棎 霐半澕 鞝滌稖霅� 瓴冹澊 鞎勲媹霛� 鞝滉车霅� 鞝曤炒鞛勳潉 雮橅儉雰呺媹雼�. 鞁犿潵 靹膘灔 旮办梾鞙茧 攵勲霅橂姅 鞚� 須岇偓電� 2025雲� 6鞗� 25鞚� 氤措弰鞛愲毳� 韱淀暣 鞚� 靻岇嫕鞚� 氚滍憸頄堨姷雼堧嫟.
KindlyMD (NASDAQ:NAKA) a d茅pos茅 un formulaire 8-K annon莽ant la nomination d鈥橝ndrew Creighton en tant que Chief Commercial Officer de Nakamoto Holdings. Le d茅p么t indique qu鈥檌l s鈥檃git d鈥檜ne divulgation conforme au Regulation FD, les informations 茅tant fournies plut么t que d茅pos茅es en vertu de la Section 18 du Securities Exchange Act. La soci茅t茅, class茅e comme une entreprise en croissance 茅mergente, a fait cette annonce via un communiqu茅 de presse le 25 juin 2025.
KindlyMD (NASDAQ:NAKA) hat ein 8-K-Formular eingereicht, in dem die Ernennung von Andrew Creighton zum Chief Commercial Officer von Nakamoto Holdings bekannt gegeben wird. Die Einreichung weist darauf hin, dass es sich um eine Offenlegung gem盲脽 Regulation FD handelt, wobei die Informationen bereitgestellt und nicht gem盲脽 Abschnitt 18 des Securities Exchange Act eingereicht wurden. Das Unternehmen, das als wachstumsstarkes Unternehmen eingestuft ist, gab diese Mitteilung am 25. Juni 2025 per Pressemitteilung bekannt.
FAQ
Who is Andrew Creighton and what is his new role at Nakamoto Holdings?
What is the relationship between KindlyMD and Nakamoto Holdings?
Is KindlyMD (NAKA) an emerging growth company?
